Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-01-10 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the third meeting of the fourth board of directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, and multiple agenda items related to the company's plan to issue shares to specific investors, including the issuance conditions, pricing, quantity, use of proceeds, and authorization for the board to handle related matters. The document also references the need to submit these matters to the shareholders' meeting for approval. The content is focused on board decisions and management-level approvals rather than financial results, audit opinions, or shareholder voting results. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a simple announcement of a report publication but a substantive board meeting resolution document. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it concerns board meeting resolutions and management decisions about capital raising and corporate actions.
2024-01-10 Chinese
第四届监事会第二次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the second meeting of the fourth supervisory board of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting's legality, attendance, and multiple agenda items related to the company's plan to issue shares to specific investors, including the issuance conditions, pricing, quantity, use of proceeds, and related reports. The document is not a full financial report but rather a formal announcement of board resolutions and plans for capital raising. It does not contain financial statements or detailed financial analysis but focuses on governance and capital issuance decisions. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2024-01-10 Chinese
前次募集资金使用情况鉴证报告
Regulatory Filings
2024-01-10 Chinese
关于公司向特定对象发行股票募集说明书（草案）的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (561 characters) regarding the company's plan to issue shares to specific investors. It mentions a draft prospectus for the share issuance and states that related documents are disclosed on the stock exchange website. It also clarifies that the announcement does not represent approval or registration by regulatory authorities yet. There is no detailed financial data or full report content, only a notification about the share issuance plan and related disclosures. According to the classification rules, this fits best under Capital/Financing Update (CAP) as it concerns fundraising activities and capital structure changes.
2024-01-10 Chinese
独立董事关于第四届董事会第三次会议相关事项的事前认可意见
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the independent directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding their prior approval opinions on various proposals related to the company's 2024 targeted stock issuance plan. It includes detailed opinions on the legality, compliance, and benefits of the stock issuance proposals, feasibility reports, fundraising usage reports, shareholder return plans, and related commitments. The document is a formal announcement of the independent directors' opinions on board meeting agenda items, specifically related to capital raising and stock issuance. It does not contain actual financial statements or detailed financial results, nor is it a transcript, audit report, or annual/interim report. The content focuses on approval opinions for proposals to be submitted to the board, which aligns with announcements related to capital/financing activities. Given the focus on stock issuance proposals and fundraising plans, the document best fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive content rather than just a notice of report publication, so it is not an RPA or RNS filing.
2024-01-10 Chinese
2024年第一次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting of shareholders (临时股东大会) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items such as approval of a private placement of shares to specific investors, authorization of the board to handle related matters, and procedural details for shareholders to attend and vote. The document is not a financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement but a formal meeting notice with agenda details. The content aligns with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or other shareholder meetings. The document length (7191 characters) and detailed meeting agenda confirm it is the meeting notice itself, not just an announcement of a report. Therefore, the classification is AGM Information (AGM-R).
2024-01-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.